Tenon Medical(R) Adds Eight New Patents Issued by the United States Patent and Trademark Office Through Q3 2026
Key Highlights
- ➤Tenon (TNON) receives eight new U.S. patents during fiscal 2026
- ➤Patent portfolio reaches 38 U.S., nine international patents, 31 pending applications
- ➤New patents protect Catamaran SI Joint Fusion System strategic systems and methods
- ➤Tenon estimates U.S. SI joint surgery market at 270,000 procedures, $2.1 billion annually
Expert Statements
Richard Ginn, Chief Technology Officer, Chief Operations Officer and Director of Tenon Medical
“Our innovation starts in the operating room. We listen closely to the physicians who use our systems and to our physician advisors, focusing our engineering on their guidance.”
Richard Ginn, Chief Technology Officer, Chief Operations Officer and Director of Tenon Medical
“These eight new patents are a direct result of that feedback. We believe that they strengthen the protection around Catamaran and, together with the rest of our portfolio, give us a strong foundation to drive procedure adoption and revenue growth as we expand care for patients with sacro-pelvic disorders.”
LOS GATOS, CA / ACCESS Newswire / October 15, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients suffering from certain sacro-pelvic disorders, today announced that the U.S. Patent and Trademark Office (USPTO) has issued 8 new patents to the Company so far in 2026 fiscal year. With these additions, Tenon holds 38 issued U.S. patents and 9 international patents and has 31 U.S. and foreign patent applications pending.
The Company believes that these 8 recently issued patents continue to solidify and strengthen the Company's position as an innovator in the rapidly growing sacro-pelvic fusion market. Encompassing both strategic systems and method claims, the patents provide underlying protection for the Company's Catamaran(®) SI Joint Fusion System, a platform that is intended to redefine the standard of care in sacroiliac joint treatment. Together, these intellectual property additions reflect Tenon's continued commitment to innovation and patient care. The Company offers a modern, integrated SI joint fusion portfolio with applications in SI joint fusion, spinal fusion, and deformity adjuncts, each engineered to help deliver reliable fusion outcomes.
Get started
Create a free account to read the full story.